BEST UNLIMITED TURBO LONG CERTIFICATE - ABBVIE | Market Closed - Euronext Paris 12:30:01 2024-06-28 pm EDT | ||
| 10.23 EUR | +2.12% |
|
| Current month | +26.76% | ||
| 1 month | +34.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ABBVIE INC.
Latest news about ABBVIE INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 10.19 | +1.74% |
| 24-06-27 | 10.02 | -6.30% |
| 24-06-26 | 10.69 | +1.32% |
| 24-06-25 | 10.55 | -3.10% |
| 24-06-24 | 10.89 | +3.69% |
Real-time Euronext Paris
Last update June 28, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ABBVIE INC. |
| Issuer | 
Société Générale
|
| PA12S | |
| ISIN | DE000SF4VFK8 |
| Date issued | 2021-09-22 |
| Strike | 116.2 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.63 € |
|---|---|
| Lowest since issue | 1.14 € |
Company Profile
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
Consensus: AbbVie Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.5
USD
Average target price
183.2
USD
Spread / Average Target
+6.83%
- Stock Market
- Certificates
- PA12S Certificat
